Cargando…

Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer

SH2 containing protein tyrosine phosphatase-2 (SHP2) is recognized as a druggable oncogenic phosphatase that is expressed in both tumor cells and immune cells. How tumor cell–autonomous SHP2 contributes to an immunosuppressive tumor microenvironment (TME) and therapeutic failure of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hao, Cresswell, Gregory M., Libring, Sarah, Ayers, Mitchell G., Miao, Jinmin, Zhang, Zhong-Yin, Solorio, Luis, Ratliff, Timothy L., Wendt, Michael K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035406/ https://www.ncbi.nlm.nih.gov/pubmed/36969745 http://dx.doi.org/10.1158/2767-9764.CRC-22-0117

Ejemplares similares

SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
por: Chen, Hao, et al.
Publicado: (2020)

Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer
por: Shinde, Aparna, et al.
Publicado: (2022)

Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche
por: Shinde, Aparna, et al.
Publicado: (2020)

4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
por: Libring, Sarah, et al.
Publicado: (2020)

In Vitro Magnetic Techniques for Investigating Cancer Progression
por: Libring, Sarah, et al.
Publicado: (2021)

Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity
por: Miao, Jinmin, et al.
Publicado: (2023)

The Dynamic Relationship of Breast Cancer Cells and Fibroblasts in Fibronectin Accumulation at Primary and Metastatic Tumor Sites
por: Libring, Sarah, et al.
Publicado: (2020)

SHP2 phosphatase as a novel therapeutic target for melanoma treatment
por: Zhang, Ruo-Yu, et al.
Publicado: (2016)

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
por: Bunda, Severa, et al.
Publicado: (2015)

Fibronectin-Expressing Mesenchymal Tumor Cells Promote Breast Cancer Metastasis
por: Jun, Brian H., et al.
Publicado: (2020)

Activating Mutation of SHP2 Establishes a Tumorigenic Phonotype Through Cell-Autonomous and Non-Cell-Autonomous Mechanisms
por: Dong, Lei, et al.
Publicado: (2021)

Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer
por: Abdullah, Ammara, et al.
Publicado: (2020)

Correction: Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer
por: Abdullah, Ammara, et al.
Publicado: (2023)

SHP2 inhibition improves celastrol-induced growth suppression of colorectal cancer
por: Zhang, Linxi, et al.
Publicado: (2022)

Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
por: Su, Jung-Chen, et al.
Publicado: (2018)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
por: Xu, Zhiyong, et al.
Publicado: (2021)

Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma
por: Li, Ye, et al.
Publicado: (2021)

Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2–Induced Gastrulation Defects
por: Jopling, Chris, et al.
Publicado: (2007)

Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
por: Zeng, Li-Fan, et al.
Publicado: (2014)

SHP‐1 suppresses endotoxin‐induced uveitis by inhibiting the TAK1/JNK pathway
por: Zhuang, Xiaonan, et al.
Publicado: (2020)

Functions of Shp2 in cancer
por: Zhang, Jie, et al.
Publicado: (2015)

Sidestepping SHP2 inhibition
por: Popescu, Bogdan, et al.
Publicado: (2023)

Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
por: Xu, Xiaozheng, et al.
Publicado: (2021)

Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization
por: Buck, Sara J. S., et al.
Publicado: (2022)

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
por: Franciosa, Giulia, et al.
Publicado: (2023)

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
por: Taylor, Julia, et al.
Publicado: (2023)

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
por: Gebregiworgis, Teklab, et al.
Publicado: (2021)

Suppression of SHP-1 promotes corticospinal tract sprouting and functional recovery after brain injury
por: Tanaka, T, et al.
Publicado: (2013)

Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling
por: Tsai, Wan-Chen, et al.
Publicado: (2015)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A
por: Zhu, Dongrong, et al.
Publicado: (2021)

Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations
por: Bauler, Timothy J., et al.
Publicado: (2011)

Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations
por: Yu, Zhi-Hong, et al.
Publicado: (2014)

Skeletal malformation and the SHP-2 pathway
Publicado: (2011)

Shp1 in Solid Cancers and Their Therapy
por: Varone, Alessia, et al.
Publicado: (2020)

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
por: Xu, Xiaozheng, et al.
Publicado: (2020)

Intraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect
por: Sun, Ziying, et al.
Publicado: (2022)

Destabilization of the SHP2 and SHP1 protein tyrosine phosphatase domains by a non-conserved “backdoor” cysteine
por: Yarnall, Matthew T.N., et al.
Publicado: (2022)

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5ged9q1lt30ea7l8pootiis0jc